PMID- 32430655
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1568-5888 (Print)
IS  - 1876-6250 (Electronic)
IS  - 1568-5888 (Linking)
VI  - 28
IP  - 6
DP  - 2020 Jun
TI  - Differences in guideline-recommended heart failure medication between Dutch heart 
      failure clinics: an analysis of the CHECK-HF registry.
PG  - 334-344
LID - 10.1007/s12471-020-01421-1 [doi]
AB  - BACKGROUND: Heart failure (HF) is associated with poor prognosis, high morbidity 
      and mortality. The prognosis can be optimised by guideline adherence, which also 
      can be used as a benchmark of quality of care. The purpose of this study was to 
      evaluate differences in use of HF medication between Dutch HF clinics. METHODS: 
      The current analysis was part of a cross-sectional registry of 10,910 chronic HF 
      patients at 34 Dutch outpatient clinics in the period of 2013 until 2016 
      (CHECK-HF), and focused on the differences in prescription rates between the 
      participating clinics in patients with heart failure with reduced ejection 
      fraction (HFrEF). RESULTS: A total of 8,360 HFrEF patients were included with 
      a mean age of 72.3 +/- 11.8 years (ranging between 69.1 +/- 11.9 and 76.6 +/- 10.0 
      between the clinics), 63.9% were men (ranging between 54.3 and 78.1%), 27.3% were 
      in New York Heart Association (NYHA) class III/IV (ranging between 8.8 and 62.1%) 
      and the average estimated glomerular filtration rate (eGFR) was 
      59.6 +/- 24.6 ml/min (ranging between 45.7 +/- 23.5 and 97.1 +/- 16.5). The 
      prescription rates ranged from 58.9-97.4% for beta blockers (p < 0.01), 
      61.9-97.1% for renin-angiotensin system (RAS) inhibitors (p < 0.01), 29.9-86.8% 
      for mineralocorticoid receptor antagonists (MRAs) (p < 0.01), 0.0-31.3% for 
      ivabradine (p < 0.01) and 64.9-100.0% for diuretics (p < 0.01). Also, the 
      percentage of patients who received the target dose differed significantly, 
      5.9-29.1% for beta blockers (p < 0.01), 18.4-56.1% for RAS inhibitors (p < 0.01) 
      and 13.2-60.6% for MRAs (p < 0.01). CONCLUSIONS: The prescription rates and 
      prescribed dosages of guideline-recommended medication differed significantly 
      between HF outpatient clinics in the Netherlands, not fully explained by 
      differences in patient profiles.
FAU - Linssen, G C M
AU  - Linssen GCM
AD  - Department of Cardiology, Hospital Group Twente, Almelo and Hengelo, Almelo, The 
      Netherlands. g.linssen@zgt.nl.
FAU - Veenis, J F
AU  - Veenis JF
AD  - Erasmus Medical Center, Department of Cardiology, University Medical Center 
      Rotterdam, Rotterdam, The Netherlands.
FAU - Brunner-La Rocca, H P
AU  - Brunner-La Rocca HP
AD  - Department of Cardiology, Maastricht University Medical Centre, Maastricht, The 
      Netherlands.
FAU - van Pol, P E J
AU  - van Pol PEJ
AD  - Department of Cardiology, Alrijne Ziekenhuis, Leiderdorp, The Netherlands.
AD  - CONNECT-HF Program, Netherlands Society of Cardiology, Utrecht, The Netherlands.
FAU - Engelen, D J M
AU  - Engelen DJM
AD  - Department of Cardiology, Diakonessenhuis, Utrecht, The Netherlands.
FAU - van Tooren, R M
AU  - van Tooren RM
AD  - Department of Cardiology, St. Antonius ziekenhuis, Nieuwegein, The Netherlands.
FAU - Koornstra-Wortel, H J J
AU  - Koornstra-Wortel HJJ
AD  - Department of Cardiology, Maasziekenhuis Pantein, Beugen (Boxmeer), The 
      Netherlands.
FAU - Hoes, A W
AU  - Hoes AW
AD  - Julius Center for Health Sciences and Primary Care, University Medical Center 
      Utrecht and Utrecht University, Utrecht, The Netherlands.
FAU - Brugts, J J
AU  - Brugts JJ
AD  - Erasmus Medical Center, Department of Cardiology, University Medical Center 
      Rotterdam, Rotterdam, The Netherlands.
CN  - CHECK-HF investigators
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - Neth Heart J
JT  - Netherlands heart journal : monthly journal of the Netherlands Society of 
      Cardiology and the Netherlands Heart Foundation
JID - 101095458
PMC - PMC7270463
OTO - NOTNLM
OT  - Adherence
OT  - Guidelines
OT  - HFmrEF
OT  - HFrEF
OT  - Heart failure
OT  - Medication
COIS- H.P. Brunner-La Rocca has received research grants from Roche Diagnostics, 
      Novartis, and Vifor. G.C.M. Linssen, J.F. Veenis, P.E.J. van Pol, D.J.M. Engelen, 
      R.M. van Tooren, H.J.J. Koornstra-Wortel, A.W. Hoes and J.J. Brugts declare that 
      they have no competing interests.
EDAT- 2020/05/21 06:00
MHDA- 2020/05/21 06:01
PMCR- 2020/05/19
CRDT- 2020/05/21 06:00
PHST- 2020/05/21 06:00 [pubmed]
PHST- 2020/05/21 06:01 [medline]
PHST- 2020/05/21 06:00 [entrez]
PHST- 2020/05/19 00:00 [pmc-release]
AID - 10.1007/s12471-020-01421-1 [pii]
AID - 1421 [pii]
AID - 10.1007/s12471-020-01421-1 [doi]
PST - ppublish
SO  - Neth Heart J. 2020 Jun;28(6):334-344. doi: 10.1007/s12471-020-01421-1.